TAS Minutes 22nd October 2024(234 KB) - TAS
Date added: 24th Jan 2025
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| TIRZEPATIDE (Mounjaro®) (NEW) | Grey | Management of overweight and obesity |
January 2025: Tirzepatide should NOT be prescribed for managing overweight and obesity.
Whilst NICE TA1026 was published in December 2024, the ICB awaits further commissioning guidance from NHS England. Further details about local implementation will be provided in due course. Until that time, tirzepatide should not be prescribed for this indication.
|
Other Updates on this Website
Recent documents from LLR APC and TAS
TAS Minutes 24th Sept 2024(228 KB) - TAS
Date added: 24th Jan 2025
TAS Minutes 27th August 2024(231 KB) - TAS
Date added: 24th Jan 2025
TAS Minutes 25th June 2024(230 KB) - TAS
Date added: 24th Jan 2025
TAS Minutes 24th April 2024(239 KB) - TAS
Date added: 24th Jan 2025
TAS Minutes 26th March 2024(246 KB) - TAS
Date added: 24th Jan 2025
LLR-APC-Newsletter-December-2024(813 KB) - LMSG/LLR APC newsletters
Date added: 22nd Jan 2025
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more